Health & Biotech

Qiagen cuts 2026 outlook as QuantiFERON immigration testing slumps

Monday, 4 May 2026 10:34AM UTC

Watch carefully: Qiagen’s latest update shows earnings holding up while a slump in immigration-related QuantiFERON testing forces the company to trim its 2026 sales outlook , a small but meaningful reset that investors and customers should understand.

Essential Takeaways

Earnings matched expectations: Adjusted diluted EPS of $0.54 at constant exchange rates met the company’s outlook, signalling resilient profitability.
Sales miss driven by QuantiFERON: Net sales were $492m, down slightly at CER, with QuantiFERON immigration testing volumes falling and trimming overall revenue.
Pillars mostly steady: Four of five strategic pillars grew or met targets; Sample Technologies and Genomics showed notable strength.
Outlook reduced: 2026 sales guidance cut to about 1–2% CER growth and adjusted EPS lowered slightly to at least $2.43 at CER.
Efficiency focus: Management points to margin-supporting cost programmes and ERP/efficiency projects expected to keep profitability on track.

Earnings held, but sales fell short , the flavour of the quarter

Qiagen posted preliminary Q1 results that delivered on adjusted EPS while missing its sales target, a contrast that felt oddly reassuring. According to the company and MarketBeat coverage, EPS landed at $0.54 at constant exchange rates, matching guidance, yet net sales of $492m grew only 2% on a reported basis and slipped 1% at CER. There’s a tangible sense that management’s cost discipline cushioned the blow, so profitability stayed intact even as top-line momentum softened.

QuantiFERON: immigration testing is the specific weak spot

The headline culprit was QuantiFERON, where sales declined about 5% at CER , and management was clear this was largely down to reduced immigration-related testing volumes in the U.S. and Middle East. That’s an important nuance: Qiagen says the shortfall is concentrated in immigration flows rather than a broad clinical weakness or pricing pressure, which makes this more of a demand rebasing than a product failure. If you follow diagnostics trends, it’s a reminder how policy and migration patterns can create lumpy revenue for specific assays.

Where strength came from , Sample Technologies and targeted growth

Not everything looked gloomy. Sample Technologies reported robust performance, helped by demand for automated consumables and instrument placements, while Genomics and QIAGEN Digital Insights chipped in with steady gains. Management cited double-digit CER growth for QIAcuity within PCR categories and highlighted new automation launches coming through this year. For investors this signals diversification: parts of the business are growing enough to offset pockets of weakness.

Guidance trimmed, but margin targets remain believable

Qiagen trimmed its 2026 sales outlook to roughly 1–2% CER growth and nudged down adjusted EPS to at least $2.43 at CER, versus prior targets. Still, the company expects adjusted EBIT margin to strengthen into the second quarter and finish the year near its margin goals, pointing to ongoing “QI-efficiency” projects and ERP rollouts. That emphasis on operational leverage is the reason management feels comfortable keeping profitability targets while accepting a more cautious top-line view.

What to watch next , product rollouts and the QuantiFERON spotlight

Qiagen plans a QuantiFERON spotlight session to detail automation and chemistry upgrades, and management flagged several product launches including new sample-prep instruments and expanded QIAstat panels. Those releases, plus an expected improvement in QuantiFERON year-over-year comparisons and the roll-off of prior headwinds, are the company’s roadmap for stronger H2 growth. If you’re tracking the stock or the diagnostics market, mark the May presentation and subsequent FDA/market updates as key catalysts.

It's a small recalibration with a clear cause: policy-driven testing volumes. For investors and customers, the takeaway is to judge Qiagen by its diversified pillars and margin discipline as much as by any single assay’s swings.

Source Reference Map

Story idea inspired by: ^[1]

Sources by paragraph:

Paragraph 1: ^[2], ^[3]
Paragraph 2: ^[2], ^[7]
Paragraph 3: ^[2], ^[3]
Paragraph 4: ^[2], ^[6]
Paragraph 5: ^[2], ^[5]

More on this

https://www.marketbeat.com/instant-alerts/qiagen-cuts-2026-outlook-as-quantiferon-immigration-testing-slumps-despite-eps-match-2026-05-03/ - Please view link - unable to able to access data
https://www.marketbeat.com/instant-alerts/qiagen-cuts-2026-outlook-as-quantiferon-immigration-testing-slumps-despite-eps-match-2026-05-03/ - Qiagen reported preliminary first-quarter 2026 results, achieving adjusted diluted earnings per share (EPS) of $0.54 at constant exchange rates, matching its outlook. Net sales were $492 million, up 2% on a reported basis but down 1% at constant exchange rates, below the company's target. The shortfall was primarily due to significantly lower QuantiFERON immigration testing demand and continued caution among U.S. life sciences customers. Despite this, four of the company's five strategic pillars met or exceeded internal expectations, with pillar sales up 4% at constant exchange rates. The company has updated its full-year 2026 outlook, now expecting net sales growth of about 1% to 2% at constant exchange rates, down from the previous expectation of at least 5% growth. Adjusted diluted EPS is now expected to be at least $2.43 at constant exchange rates, compared to the prior target of at least $2.50.
https://www.biospace.com/press-releases/qiagen-reports-preliminary-q1-2026-results-achieves-adjusted-eps-outlook-with-mixed-sales-trends-updates-full-year-2026-outlook - Qiagen announced preliminary results for the first quarter of 2026, achieving adjusted diluted earnings per share (EPS) of $0.54 at constant exchange rates, in line with its outlook. Net sales were $492 million, up 2% on a reported basis but down 1% at constant exchange rates, below the company's target. The decline was mainly due to significantly lower QuantiFERON immigration testing demand and cautious U.S. life sciences customer spending. Despite this, four of the company's five strategic pillars met or exceeded internal expectations, with pillar sales up 4% at constant exchange rates. The company has updated its full-year 2026 outlook, now expecting net sales growth of about 1% to 2% at constant exchange rates, down from the previous expectation of at least 5% growth. Adjusted diluted EPS is now expected to be at least $2.43 at constant exchange rates, compared to the prior target of at least $2.50.
https://www.finanzwire.com/article/qiagen-nv-etr-qia-qiagen-revises-2026-outlook-amid-mixed-q1-results-bOwrfxnOh1n - Qiagen N.V. announced its preliminary results for the first quarter of 2026, showing a mixed performance. The company met its adjusted diluted earnings per share (EPS) outlook, with net sales reaching $492 million, a 2% increase on a reported basis but a 1% decrease at constant exchange rates compared to its growth target. The company's growth pillars saw a 4% increase at constant exchange rates, highlighted by a 9% growth in sample technologies. Despite these gains, QuantiFERON sales decreased by 5% at constant exchange rates due to reduced immigration testing in the U.S. and the Middle East. In response, Qiagen has lowered its full-year forecast for 2026, with net sales growth expected to be between 1-2% at constant exchange rates and adjusted diluted EPS to be at least $2.43 at constant exchange rates. The company projects stronger performance in the second half of 2026, driven by new product launches and diminishing past headwinds.
https://corporate.qiagen.com/English/investor-relations/events-and-presentations/events/2026/Full-Q1-2026-Results/default.aspx - Qiagen N.V. has scheduled the release of its full first-quarter 2026 results on May 6, 2026, at 10:05 PM CET. The company will provide detailed financial information and insights into its performance during the quarter. Investors and stakeholders can access the press release and related materials on Qiagen's official investor relations website. The earnings call is scheduled for May 7, 2026, at 9:00 AM ET, where company executives will discuss the results and address questions from analysts and investors.
https://www.marketbeat.com/earnings/reports/2026-4-28-qiagen-stock/ - Qiagen (NYSE:QGEN) issued an update on its first quarter 2026 earnings guidance, providing earnings per share guidance of $0.54, in line with consensus estimates. The company reported $0.62 earnings per share for the prior quarter, beating estimates by $0.01. Qiagen's revenue for the quarter was $540.42 million, compared to the consensus estimate of $528.53 million, marking a 3.6% year-over-year increase. The company's full-year 2026 guidance includes an adjusted diluted EPS of at least $2.50. Analysts have set a consensus price target of $53.64 for Qiagen's stock, with an average rating of 'Hold'.
https://www.sec.gov/Archives/edgar/data/1015820/000101582026000024/exhibit991q12026preliminar.htm - The U.S. Securities and Exchange Commission (SEC) has published Qiagen's preliminary first-quarter 2026 results, detailing the company's financial performance for the period. The report includes information on adjusted diluted earnings per share (EPS), net sales, and segment performance. It also provides insights into the factors influencing the company's results, such as QuantiFERON sales and U.S. life sciences customer demand. The SEC filing offers a comprehensive overview of Qiagen's financial health and strategic outlook for the remainder of 2026.

Noah Fact Check Pro

The draft above was created using the information available at the time the story first emerged. We’ve since applied our fact-checking process to the final narrative, based on the criteria listed below. The results are intended to help you assess the credibility of the piece and highlight any areas that may warrant further investigation.

Freshness check

Score: 8

Notes: The article references Qiagen's preliminary Q1 2026 results and the subsequent revision of its 2026 outlook, with the latest publication date being May 3, 2026. This suggests the content is current and not recycled. However, the article heavily relies on a press release from Qiagen dated April 27, 2026, which may limit its originality. The MarketBeat article from May 3, 2026, appears to be a direct summary of the press release, indicating a lack of independent reporting. This reliance on a single source raises concerns about the independence and originality of the content.

Quotes check

Score: 6

Notes: The article includes direct quotes attributed to Qiagen's CEO Thierry Bernard and CFO Roland Sackers. These quotes are consistent with those found in Qiagen's press release dated April 27, 2026. No earlier instances of these exact quotes were found, suggesting they are original. However, the absence of independent verification of these quotes raises concerns about their authenticity. The reliance on a single source for these quotes diminishes their credibility.

Source reliability

Score: 5

Notes: The primary source of the article is a press release from Qiagen, which is inherently biased and serves as promotional material. The MarketBeat article from May 3, 2026, appears to be a direct summary of this press release, indicating a lack of independent reporting. The reliance on a single, potentially biased source raises concerns about the reliability and objectivity of the information presented.

Plausibility check

Score: 7

Notes: The article reports on Qiagen's preliminary Q1 2026 results and the revision of its 2026 outlook, citing a decline in QuantiFERON sales due to reduced immigration testing demand. These claims are plausible and align with the information provided in Qiagen's press release. However, the lack of independent verification and the heavy reliance on a single source raise questions about the accuracy and completeness of the information.

Overall assessment

Verdict (FAIL, OPEN, PASS): FAIL

Confidence (LOW, MEDIUM, HIGH): HIGH

Summary: The article heavily relies on Qiagen's press release and a MarketBeat article summarizing it, with no independent verification or reporting from other reputable sources. This lack of independent reporting and verification raises significant concerns about the credibility, reliability, and originality of the information presented. The reliance on a single, potentially biased source diminishes the overall trustworthiness of the content.